Paying for Gene Therapy

Posted by Ed Schoonveld on Wed, Jun 27, 2018

Recent advancements in gene and cell therapies have raised both excitement and anxiety in the global medical community. Luxterna (voretigene neparvovec-rzyl) and CAR-T therapies Kymria (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) have provided potential cures for a significant share of patients with just a single treatment. However, that single treatment, with amazing patient value delivered over years or even decades, also requires a single payment under our current healthcare funding mechanisms. This is causing some additional complexities in an already complex and sensitive prescription drug pricing environment.


>
Read More

European Drug Pricing Alliances: Force or Farce?

Posted by Ed Schoonveld on Thu, Mar 01, 2018

Affordability of health care for an aging population, the emergence of innovative drugs with promising impact on patient lives and the continuing concerns over prescription drug costs have resulted in a deluge of political attention to drug pricing around the world. Immediately following the launch of Gilead’s Sovaldi, European governments declared an intent to more intensely collaborate on drug price negotiations. The Netherlands, Belgium and Luxembourg (later joined by Austria) created an alliance to jointly negotiate with the pharmaceutical industry. Today, the landscape has evolved further. What are the implications of pricing alliances for pharma companies? Will this evolve to one European price negotiation? Or will it disintegrate as countries fail to agree on common standards? Let’s analyze.


>
Read More

2017 Fair Pricing Forum: The Message for Pharma CEOs

Posted by Ed Schoonveld on Tue, Jul 18, 2017

This article was originally published in the June 2017 issue of In Vivo.

Drug pricing continues to be a social and political dilemma that forms a divide between the drug industry on one side and medical community, governments and patients on the other side. Frustrations over the high cost of prescription drugs have resulted in a groundswell of government and private initiatives to increase transparency, analyze value through various frameworks or directly control pricing.


>
Read More

Five Observations From the 2017 Fair Pricing Forum

Posted by Ed Schoonveld on Mon, May 15, 2017

In May, I joined various members of governmental organizations, patient organizations and the life sciences industry at the 2017 Fair Pricing Forum, an invitation-only meeting to discuss “fair pricing” for medications in Amsterdam. Organized by the World Health Organization and the Dutch Ministry of Health, the meeting prompted a productive dialogue among stakeholders but also revealed a worrisome gap in the overall perception of the drug pricing discussion. The pharmaceutical industry’s viewpoint was widely underrepresented, with attendance heavily weighted toward governments and activists, and only a small industry delegation.


>
Read More